Agilex Biolabs, Australia’s most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, today announced the roll-out of the GALEXI™ client portal for real-time study management.
Agilex Biolabs, Australia’s most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, today announced the roll-out of the GALEXI™ client portal for real-time study management.
Agilex Biolabs is the leading bioanalytical laboratory in Asia-Pacific with the most advanced platforms for sensitive technologies. They include Sciex API 6500+ LC-MS/MS, Sciex API 4000 LC-MS/MS systems; Gyrolab™ Xplore, Luminex MAGPIX xPONENT ™, MSD Quickplex 120 and BD FACSymphony™ A3 20 colour flow cytometry analysers, so we have the capability to deliver any sized project.
Register here (free)...
Agilex Biolabs, the leading APAC biolabs for biotech clinical trials, announced today the launch of a Client Portal named GALEXI™.
The Agilex Biolabs technology team, with its Microsoft partner, accelerated the launch of GALEXI™ to deliver secure and enhanced communications during continued COVID challenges globally.
The Agilex Biolabs technology team, with its Microsoft partner, accelerated the launch of GALEXI™ to deliver secure and enhanced communications during continued COVID challenges globally.
Agilex Biolabs, Australia’s most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, congratulates client company Shasqi on the announcement of the first-ever application of click chemistry in humans, with the launch of the Company’s lead clinical candidate, SQ3370. Shasqi is the first Y Combinator-backed biotech company to reach clinical development.
Title: Development and Validation of a PK Method for Tocilizumab in Both Singlicate and Duplicate on the Gyrolab Platform
Agilex Biolabs, Australia’s most advanced specialist bioanalytical laboratory for clinical trials, congratulated client Zelira Therapeutics on their Phase 2 Medicinal Cannabis Insomnia Study.
Why Australia is the World’s Leading Early Phase Destination – Rapid Start-up, No IND Required, and a Government-Backed Refund on Almost Half of all Trial Costs Increasingly Sponsors are wanting to be actively involved in the core clinical partner selection because they matter to the success of their clinical research.
Hi, everyone. I'm Arsalan Arif, the publisher of Endpoints News, and I'm pleased to be your moderator today. Today's webinar is sponsored by Agilex Biolabs in Australia. Our topic is Why Australia is the World's Leading Early Phase Destination - Rapid Start-up, No IND Required, and a Government-Backed Refund on Almost Half of all Trial Costs. I'm joined by two great guests today. Kurt Sales, the Director of Immunoassay at Agilex Biolabs, and Jane Kelly, the CEO of CMAX Clinical Research.
